Table 2.

Impact of PCLX-001 treatment on T cells, B cells, and monocyte population.

Cell Populations	Screening Sample (%)	Day 1 (%)	Day 28 (%)
Total T cells	66.6 ± 0.52	66.7 ± 0.51	70.1 ± 0.50
CD4+ T cells	40.2 ± 0.24	42.5 ± 0.24	46.8 ± 0.22
CD8+ T cells	25.1 ± 0.33	23.1 ± 0.34	22.5 ± 0.31
CD19+ B cells	0.71 ± 0.66	1.18 ± 0.51	0.59 ± 0.50
CD14+ monocytes	5.01 ± 0.4	14.2 ± 0.40	4.51 ± 0.42

PBMC were isolated from patient 1 after 28 days of treatment with PCLX-001 and analysed by flow cytometry. Extracellular staining allowed us to analyse the proportion of live total T cells (CD3+), CD4+ T cells, CD8+ T cells (A), B cells (CD19+), and monocytes (CD14+). Values are expressed as % of population ± CV.